Radius Health
Focus: Radius Health is a publicly traded biotechnology company headquartered in Boston specializing in small molecules and biologics for endocrinology and oncology. The company operates at peak revenue concentration with TYMLOS (abaloparatide) generating nearly all commercial revenue.
Profile data last refreshed 16h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Radius Health
AI assessmentNot HiringNo open roles listed right now. Follow Radius Health to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Radius Health's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$198M Part DStable
Peak13.2yr
Cornerstone commercial asset generating 100% of company revenue; small-molecule PTH analog with 16-year patent exclusivity runway.
Help build intelligence for Radius Health
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.